ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,308.15
1.17%
US Tech 100
18,138.40
1.69%
다우존스 지수
39,908.00
0.88%
Bitcoin
65,808.51
-0.68%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 유럽
  5. EU
  6. Transgene SA (TNG)

  7. Transgene SA (TNG) 뉴스

TNG

Transgene (TNG)

Transgene SA
일자:
정렬 기준:
 검색 관련기사 보기:EU:TNG
일자시간출처헤드라인심볼기업
2024/05/1600:45GlobeNewswire Inc.Transgene’s Combined General Meeting of May 15, 2024EU:TNGTransgene SA
2024/05/1600:45GlobeNewswire Inc.Assemblée Générale Mixte de Transgene du 15 mai 2024EU:TNGTransgene SA
2024/05/1600:45GlobeNewswire Inc.Transgene’s Combined General Meeting of May 15, 2024EU:TNGTransgene SA
2024/05/1500:45GlobeNewswire Inc.Transgene fait le point sur ses activités et sa situation financière au premier trimestre 2024EU:TNGTransgene SA
2024/05/1500:45GlobeNewswire Inc.Transgene provides business and financial update for Q1 2024EU:TNGTransgene SA
2024/05/1500:45GlobeNewswire Inc.Transgene provides business and financial update for Q1 2024EU:TNGTransgene SA
2024/04/2500:45GlobeNewswire Inc.Mise à disposition des documents préparatoires à l'Assemblée générale du 15 mai 2024EU:TNGTransgene SA
2024/04/2500:45GlobeNewswire Inc.Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024EU:TNGTransgene SA
2024/04/2500:45GlobeNewswire Inc.Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024EU:TNGTransgene SA
2024/04/1202:05GlobeNewswire Inc.Document d'enregistrement Universel 2023EU:TNGTransgene SA
2024/04/1200:45GlobeNewswire Inc.MIse à disposition du document d'enregistrement universel 2023 de TransgeneEU:TNGTransgene SA
2024/04/1200:45GlobeNewswire Inc.Availability of Transgene's 2023 Universal Registration DocumentEU:TNGTransgene SA
2024/04/1000:45GlobeNewswire Inc.Transgene et NEC présentent les premiers signes de bénéfice clinique de leur vaccin individualisé contre le cancer, TG4050, dans les cancers de la tête et du cou à l’AACR 2024EU:TNGTransgene SA
2024/04/1000:45GlobeNewswire Inc.Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024EU:TNGTransgene SA
2024/04/1000:45GlobeNewswire Inc.Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024EU:TNGTransgene SA
2024/03/2801:45GlobeNewswire Inc.Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources OfficerEU:TNGTransgene SA
2024/03/2801:45GlobeNewswire Inc.Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025EU:TNGTransgene SA
2024/03/2801:45GlobeNewswire Inc.Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025EU:TNGTransgene SA
2024/03/2801:45GlobeNewswire Inc.Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources OfficerEU:TNGTransgene SA
2024/03/2801:45GlobeNewswire Inc.Transgene nomme Lucie Larguier en tant que Directrice Financière et Christelle Schwoerer Comme Directrice des Ressources HumainesEU:TNGTransgene SA
2024/03/2801:45GlobeNewswire Inc.Transgene prévoit des avancées significatives sur son portefeuille d’immunothérapies en 2024 et étend sa visibilité financière jusqu’au 4ème trimestre 2025EU:TNGTransgene SA
2024/03/1901:45GlobeNewswire Inc.Transgene annonce ses prochaines rencontres avec les investisseursEU:TNGTransgene SA
2024/03/1901:45GlobeNewswire Inc.Transgene Announces Upcoming Investor MeetingsEU:TNGTransgene SA
2024/03/1901:45GlobeNewswire Inc.Transgene Announces Upcoming Investor MeetingsEU:TNGTransgene SA
2024/03/0615:30GlobeNewswire Inc.Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024EU:TNGTransgene SA
2024/03/0615:30GlobeNewswire Inc.Transgene présentera de nouvelles données sur son vaccin individualisé TG4050 à l’AACR 2024EU:TNGTransgene SA
2024/03/0615:30GlobeNewswire Inc.Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024EU:TNGTransgene SA
2024/03/0515:30GlobeNewswire Inc.Transgene, NEC et BostonGene étendent leur collaboration dans le cadre de l’essai clinique de Phase I/II du vaccin individualisé TG4050EU:TNGTransgene SA
2024/03/0515:30GlobeNewswire Inc.Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050EU:TNGTransgene SA
2024/03/0515:30GlobeNewswire Inc.Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050EU:TNGTransgene SA
 검색 관련기사 보기:EU:TNG

최근 히스토리

CCOM
US500
US 500
NYSE
KO
Coca Cola
NASDAQ
TSLA
Tesla
AMEX
XLV
Health Care Select Sector
CCOM
US30
US 30
NYSE
XOM
Exxon Mobil
NASDAQ
AMZN
Amazon.com
NASDAQ
AAPL
Apple
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
DIS
Walt Disney
NYSE
MRK
Merck
NYSE
BAC
Bank of America
USOTC
BASFY
BASF (QX)
COIN
ETHUSD
Ethereum
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유